Testing essential if trastuzumab therapy to be worth it

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.449, 2004-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Testing essential if trastuzumab therapy to be worth it

By  

Inpharma, Vol. 1, Iss. 1432, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Pharmacodiagnostic Testing in Breast Cancer: Focus on HER2 and Trastuzumab Therapy

By Bartlett John M.S.  

American Journal of PharmacoGenomics, Vol. 5, Iss. 5, 2005-01 ,pp. : 303-315

Adis International

Access to resources Recommend Favorite

Genetic testing before therapy may be worth it in severe MDD . . .

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 638, 2011-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Medication therapy management worth the effort

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 579, 2009-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Docetaxel/trastuzumab combination therapy for the treatment of breast cancer

By Nabholtz Jean-marc   Gligorov Joseph  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 9, 2005-08 ,pp. : 1555-1564

Informa Healthcare

Access to resources Recommend Favorite